Introduction:
Leading pharma company’s biologics arm has received U.S. FDA approval for Jobevne™, a biosimilar to Avastin®, used in treating various cancers by inhibiting tumor angiogenesis and expanding its oncology portfolio in the U.S.
Also Read: Navratna PSU stock to watch after it signs MoU with DP World
Share price movement of Biocon:
On April 9, 2025, Biocon Ltd. opened at ₹315.05, down 2.28% from its previous close of ₹322.40. The stock reached a high of ₹315.80 and a low of ₹303.85. By 4:00 PM, it traded at ₹305.20, marking a 5.33% decline, with a market cap of ₹36,642.31 crore.
Biocon Biologics Secures USFDA Nod for Cancer Drug Jobevne™:
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has received U.S. FDA approval for Jobevne™ (bevacizumab-nwgd), a biosimilar of Avastin, for intravenous treatment of multiple cancer types.
Jobevne™ is a recombinant humanized monoclonal antibody and a VEGF inhibitor. It blocks VEGF interaction with its receptors, preventing angiogenesis and limiting blood supply to tumors, thereby supporting cancer treatment.
With this approval, Biocon Biologics expands its U.S. oncology biosimilar portfolio, which includes OGIVRI and FULPHILA. The company also markets Bevacizumab as ABEVMY in Europe and Canada since 2021.
Recent news on Biocon:
As of April 04, 2025, Biocon Ltd.’s board approved raising up to ₹600 crore through issuance of commercial papers in multiple tranches on a private placement basis, according to a regulatory filing.
Stock performance of Biocon for Period of 1 week, 6 months, and 1 year:
Biocon Ltd. delivered an -11.4% return over the past week, declined by 11.5% in the past six months, and gained 10.1% over the past year.
Also Read: Railway Stock: Oriental Rail Infra secures order worth ₹3.99 Cr from Rail Coach Factory
Shareholding pattern of Biocon:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 60.60% | 60.60% | 60.60% |
| FII | 5.70% | 6% | 6% |
| DII | 15.40% | 14% | 14.30% |
| Public | 18.10% | 18.70% | 18.90% |
| Others | 0.20% | 0% | 0% |
About Biocon:
Biocon Biologics Ltd. (NSE: BIOCON), a subsidiary of Biocon Ltd., is a global biosimilars leader offering affordable biologics across 120+ countries, with a strong pipeline spanning oncology, immunology, and other critical therapeutic areas.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
